4g93
From Proteopedia
(Difference between revisions)
Line 1: | Line 1: | ||
- | + | ==CRYSTAL STRUCTURE OF THE HUMAN HEPATITIS B VIRUS T = 4 CAPSID, ADYW STRAIN, in COMPLEX WITH THE PHENYLPROPENAMIDE ASSEMBLY ACCELERATOR AT-130== | |
- | + | <StructureSection load='4g93' size='340' side='right' caption='[[4g93]], [[Resolution|resolution]] 4.20Å' scene=''> | |
- | + | == Structural highlights == | |
+ | <table><tr><td colspan='2'>[[4g93]] is a 4 chain structure with sequence from [http://en.wikipedia.org/wiki/Hepatitis_b_virus_subtype_adyw Hepatitis b virus subtype adyw]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4G93 OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4G93 FirstGlance]. <br> | ||
+ | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=0YP:N-[(1E)-1-BROMO-1-(2-METHOXYPHENYL)-3-OXO-3-(PIPERIDIN-1-YL)PROP-1-EN-2-YL]-4-NITROBENZAMIDE'>0YP</scene></td></tr> | ||
+ | <tr id='related'><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat">[[2g33|2g33]], [[2g34|2g34]]</td></tr> | ||
+ | <tr id='gene'><td class="sblockLbl"><b>[[Gene|Gene:]]</b></td><td class="sblockDat">C ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=10419 Hepatitis B virus subtype adyw])</td></tr> | ||
+ | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4g93 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4g93 OCA], [http://www.rcsb.org/pdb/explore.do?structureId=4g93 RCSB], [http://www.ebi.ac.uk/pdbsum/4g93 PDBsum]</span></td></tr> | ||
+ | </table> | ||
+ | <div style="background-color:#fffaf0;"> | ||
+ | == Publication Abstract from PubMed == | ||
+ | Hepatitis B virus (HBV) is a major cause of liver disease. Assembly of the HBV capsid is a critical step in virus production and an attractive target for new antiviral therapies. We determined the structure of HBV capsid in complex with AT-130, a member of the phenylpropenamide family of assembly effectors. AT-130 causes tertiary and quaternary structural changes but does not disrupt capsid structure. AT-130 binds a hydrophobic pocket that also accommodates the previously characterized heteroaryldihydropyrimidine compounds but favors a unique quasiequivalent location on the capsid surface. Thus, this pocket is a promiscuous drug-binding site and a likely target for different assembly effectors with a broad range of mechanisms of activity. That AT-130 successfully decreases virus production by increasing capsid assembly rate without disrupting capsid structure delineates a paradigm in antiviral design, that disrupting reaction timing is a viable strategy for assembly effectors of HBV and other viruses. | ||
- | + | Assembly-directed antivirals differentially bind quasiequivalent pockets to modify hepatitis B virus capsid tertiary and quaternary structure.,Katen SP, Tan Z, Chirapu SR, Finn MG, Zlotnick A Structure. 2013 Aug 6;21(8):1406-16. doi: 10.1016/j.str.2013.06.013. Epub 2013, Jul 18. PMID:23871485<ref>PMID:23871485</ref> | |
- | + | ||
- | + | From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | |
- | + | </div> | |
- | + | == References == | |
- | == | + | <references/> |
- | + | __TOC__ | |
+ | </StructureSection> | ||
[[Category: Hepatitis b virus subtype adyw]] | [[Category: Hepatitis b virus subtype adyw]] | ||
- | [[Category: Katen, S P | + | [[Category: Katen, S P]] |
- | [[Category: Zlotnick, A | + | [[Category: Zlotnick, A]] |
[[Category: Assembly accelerator]] | [[Category: Assembly accelerator]] | ||
[[Category: Assembly effector]] | [[Category: Assembly effector]] |
Revision as of 11:01, 21 December 2014
CRYSTAL STRUCTURE OF THE HUMAN HEPATITIS B VIRUS T = 4 CAPSID, ADYW STRAIN, in COMPLEX WITH THE PHENYLPROPENAMIDE ASSEMBLY ACCELERATOR AT-130
|